Back to top
more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$3.66 USD

3.66
1,585,684

+0.10 (2.81%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore

Tirthankar Chakraborty headshot

After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys

by Tirthankar Chakraborty

After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.

All You Need to Know About AcelRx Pharmaceuticals (ACRX) Rating Upgrade to Buy

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q4 Earnings Expected to Decline

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.

AcelRx Pharmaceuticals (ACRX) Stock Moves -1.14%: What You Should Know

by Zacks Equity Research

In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.73, marking a -1.14% move from the previous day.

AcelRx Pharmaceuticals (ACRX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.91, marking a -0.78% move from the previous day.

Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

by Zacks Equity Research

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

by Zacks Equity Research

The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).

Catalyst Gives Preliminary Firdapse Estimates & Other Updates

by Zacks Equity Research

Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.

Sanghamitra Saha headshot

Have Faith in Rising P/E: Play 5 Top-Ranked Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top Ranked Momentum Stocks to Buy for January 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 3rd

Jazz Enrolls First Patient in Phase II/III Leukemia Study

by Zacks Equity Research

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

by Zacks Equity Research

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

AcelRx Pharmaceuticals, Inc. (ACRX) has been struggling lately, but the selling pressure may be coming to an end soon.

AcelRx Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research

AcelRx Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 30.43% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 30.43% and -39.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate AcelRx Pharmaceuticals (ACRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for AcelRx (ACRX) This Earnings Season?

by Zacks Equity Research

AcelRx (ACRX) will provide updates on the launch and sales of Dsuvia when it releases second-quarter 2019 results.

Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I

by Zacks Equity Research

Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.